[{"id":"3ba5c955-8ec9-4668-a6f6-e10f2a3b745e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07004075","created_at":"2025-06-07T14:43:33.080Z","updated_at":"2025-06-07T14:43:33.080Z","phase":"Phase 3","brief_title":"FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration","source_id_and_acronym":"NCT07004075","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • temozolomide • Ivesa (firmonertinib) • Fu Mai Ning (luvometinib) • vindesine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-06-04"},{"id":"60285342-2abd-4c7a-b94c-e28c921f8a0e","acronym":"Better Brain","url":"https://clinicaltrials.gov/study/NCT06728865","created_at":"2025-02-26T10:02:54.981Z","updated_at":"2025-02-26T10:02:54.981Z","phase":"Phase 2","brief_title":"Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study","source_id_and_acronym":"NCT06728865 - Better Brain","lead_sponsor":"Li-kun Chen","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 09/04/2024","start_date":" 09/04/2024","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-12-11"},{"id":"59529bbb-f615-4981-937f-6ac29b7ec1c3","acronym":"PIKACHU","url":"https://clinicaltrials.gov/study/NCT04322890","created_at":"2021-01-18T20:56:40.742Z","updated_at":"2024-07-02T16:34:59.292Z","phase":"Phase 2","brief_title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","source_id_and_acronym":"NCT04322890 - PIKACHU","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2027","study_completion_date":" 12/24/2027","last_update_posted":"2024-06-04"},{"id":"93f98008-2763-4eb8-b3d9-f6477ef24b99","acronym":"FURMO-002","url":"https://clinicaltrials.gov/study/NCT05364073","created_at":"2022-05-06T18:55:07.280Z","updated_at":"2024-07-02T16:35:02.618Z","phase":"Phase 1","brief_title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","source_id_and_acronym":"NCT05364073 - FURMO-002","lead_sponsor":"ArriVent BioPharma, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-20"},{"id":"f3aa5ebc-ff8a-48a1-8ade-20d99888b813","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821933","created_at":"2023-04-20T14:03:56.574Z","updated_at":"2024-07-02T16:35:10.455Z","phase":"Phase 1/2","brief_title":"RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC","source_id_and_acronym":"NCT05821933","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Ivesa (firmonertinib) • RC108"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-04-10"},{"id":"d6a118c2-8cf3-4103-9203-82d15917f3c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06185400","created_at":"2023-12-29T18:18:16.940Z","updated_at":"2024-07-02T16:35:24.913Z","phase":"Phase 2","brief_title":"RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations","source_id_and_acronym":"NCT06185400","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Irene (pyrotinib) • Ameile (aumolertinib) • Aidixi (disitamab vedotin) • Ivesa (firmonertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-12-29"},{"id":"7d41bb5c-8775-4bbb-9bda-315d6ca7d0d0","acronym":"SELECT-2","url":"https://clinicaltrials.gov/study/NCT04401059","created_at":"2023-12-27T18:16:50.631Z","updated_at":"2024-07-02T16:35:25.073Z","phase":"Phase 4","brief_title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study","source_id_and_acronym":"NCT04401059 - SELECT-2","lead_sponsor":"Tian Xie","biomarkers":" EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR positive","tags":["EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • erlotinib • gefitinib • Conmana (icotinib) • Ameile (aumolertinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 744","initiation":"Initiation: 11/09/2020","start_date":" 11/09/2020","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2023-12-27"},{"id":"7f07b058-ffe9-4572-8792-c65fb102a298","acronym":"","url":"https://clinicaltrials.gov/study/NCT06117644","created_at":"2023-11-07T20:13:16.847Z","updated_at":"2024-07-02T16:35:30.289Z","phase":"","brief_title":"The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC","source_id_and_acronym":"NCT06117644","lead_sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Ivesa (firmonertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-11-06"},{"id":"5de9da0b-6a2d-444a-a821-f9bbc72dd2fb","acronym":"FORCE","url":"https://clinicaltrials.gov/study/NCT05379803","created_at":"2022-05-18T11:56:59.797Z","updated_at":"2024-07-02T16:35:39.839Z","phase":"Phase 2","brief_title":"High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases","source_id_and_acronym":"NCT05379803 - FORCE","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2023-08-16"},{"id":"0bf69b90-48c2-4d9a-b542-53d3e07a709b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05987826","created_at":"2023-08-14T15:10:13.324Z","updated_at":"2024-07-02T16:35:40.176Z","phase":"Phase 2","brief_title":"Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC","source_id_and_acronym":"NCT05987826","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-14"},{"id":"332d2bde-3cf8-4674-9b54-0fb1c12bee19","acronym":"","url":"https://clinicaltrials.gov/study/NCT05847764","created_at":"2023-05-08T15:03:50.146Z","updated_at":"2024-07-02T16:35:48.761Z","phase":"Phase 2","brief_title":"Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations","source_id_and_acronym":"NCT05847764","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin) • Ivesa (firmonertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-05-08"},{"id":"eced6ff3-eb59-4479-abc1-1ecf256e2ffb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05445310","created_at":"2022-07-06T15:54:35.837Z","updated_at":"2024-07-02T16:35:55.397Z","phase":"Phase 2","brief_title":"Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05445310","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L858R + EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L858R + EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 08/06/2022","start_date":" 08/06/2022","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-02-16"},{"id":"32bb9ec0-8ece-4ff0-9eed-ca43734f4ecf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05466149","created_at":"2022-07-20T13:55:18.514Z","updated_at":"2024-07-02T16:35:56.577Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion","source_id_and_acronym":"NCT05466149","lead_sponsor":"Allist Pharmaceuticals, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/27/2022","start_date":" 09/27/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-01"},{"id":"1cdea88e-fa8b-42ad-b6b5-e74c04254d8b","acronym":"FAVOUR","url":"https://clinicaltrials.gov/study/NCT04858958","created_at":"2021-04-26T12:52:43.637Z","updated_at":"2024-07-02T16:35:57.450Z","phase":"Phase 1","brief_title":"Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation","source_id_and_acronym":"NCT04858958 - FAVOUR","lead_sponsor":"Allist Pharmaceuticals, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/10/2020","start_date":" 08/10/2020","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-01-18"},{"id":"cb4de4ac-f5fd-4b02-9587-cbd8ee6af362","acronym":"FOCUS-A","url":"https://clinicaltrials.gov/study/NCT04895930","created_at":"2021-05-20T11:54:10.599Z","updated_at":"2024-07-02T16:35:58.044Z","phase":"Phase 2","brief_title":"Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC","source_id_and_acronym":"NCT04895930 - FOCUS-A","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 10/12/2021","start_date":" 10/12/2021","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2023-01-06"},{"id":"df108a82-a267-4dee-adf2-6425e67269e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05548348","created_at":"2022-09-21T18:56:17.908Z","updated_at":"2024-07-02T16:36:03.669Z","phase":"Phase 2","brief_title":"First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation","source_id_and_acronym":"NCT05548348","lead_sponsor":"Chongqing University Cancer Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/26/2022","start_date":" 09/26/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2022-09-21"},{"id":"6540af51-08c8-4ea9-8f7a-abc967b71c63","acronym":"FOCUS-C","url":"https://clinicaltrials.gov/study/NCT05334277","created_at":"2022-04-19T23:53:59.859Z","updated_at":"2024-07-02T16:36:04.704Z","phase":"Phase 2","brief_title":"Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA","source_id_and_acronym":"NCT05334277 - FOCUS-C","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • pemetrexed • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 05/06/2022","start_date":" 05/06/2022","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2022-08-31"},{"id":"8c5f0c5e-9d80-4ed8-98de-cf3b5d3adb3a","acronym":"LungMate-012","url":"https://clinicaltrials.gov/study/NCT05503667","created_at":"2022-08-17T14:55:08.386Z","updated_at":"2024-07-02T16:36:05.360Z","phase":"Phase 2","brief_title":"Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma","source_id_and_acronym":"NCT05503667 - LungMate-012","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 02/01/2022","start_date":" 02/01/2022","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2022-08-17"},{"id":"4e823454-448d-4b7e-9e12-66bb746c8674","acronym":"","url":"https://clinicaltrials.gov/study/NCT05255406","created_at":"2022-02-24T13:52:49.002Z","updated_at":"2024-07-02T16:36:06.023Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)","source_id_and_acronym":"NCT05255406","lead_sponsor":"Fudan University","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-08-04"},{"id":"2691d3bd-7c30-47aa-82d7-457b965a72bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05430802","created_at":"2022-06-24T15:56:34.292Z","updated_at":"2024-07-02T16:36:08.353Z","phase":"Phase 2","brief_title":"Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)","source_id_and_acronym":"NCT05430802","lead_sponsor":"Tang-Du Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/24/2022","start_date":" 02/24/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2022-06-24"},{"id":"b9ade31e-da99-4456-abc7-fe5c96a40dfb","acronym":"ATHEM","url":"https://clinicaltrials.gov/study/NCT05165355","created_at":"2021-12-21T15:53:35.745Z","updated_at":"2024-07-02T16:36:18.383Z","phase":"Phase 2","brief_title":"Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma","source_id_and_acronym":"NCT05165355 - ATHEM","lead_sponsor":"Tongji University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 12/28/2021","start_date":" 12/28/2021","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2022-01-17"},{"id":"c86f9912-a37d-4f5e-81a3-30db97fcaa1f","acronym":"FAVOUR2","url":"https://clinicaltrials.gov/study/NCT04958967","created_at":"2021-07-12T15:53:08.483Z","updated_at":"2024-07-02T16:36:22.514Z","phase":"Phase 1","brief_title":"Phase Ib Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation","source_id_and_acronym":"NCT04958967 - FAVOUR2","lead_sponsor":"Allist Pharmaceuticals, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 05/01/2022","primary_completion_date":" 05/01/2022","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2021-10-25"},{"id":"c4f7c4ff-0d78-4a7c-991f-85afb86bd89f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05079022","created_at":"2021-10-15T14:52:57.375Z","updated_at":"2024-07-02T16:36:22.956Z","phase":"Phase 1/2","brief_title":"ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas","source_id_and_acronym":"NCT05079022","lead_sponsor":"Peking University People's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2021-10-15"},{"id":"5b3ec336-65da-4916-99b0-e6eaa4adb964","acronym":"TERMGGO","url":"https://clinicaltrials.gov/study/NCT04982900","created_at":"2021-07-29T14:53:20.430Z","updated_at":"2024-07-02T16:36:23.477Z","phase":"Phase 2","brief_title":"Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities","source_id_and_acronym":"NCT04982900 - TERMGGO","lead_sponsor":"Ruijin Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2021-10-05"}]